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Abstract
Background—Eosinophilic gastroenteritis is a rare condition where eosinophilic inflammation 
occurs in the gastrointestinal tract in the absence of secondary causes. Little is known regarding 
aetiology, pathogenesis, or natural history.
Aims—To characterize the clinical, endoscopic, and histopathologic features of eosinophilic 
gastroenteritis and to summarize treatment outcomes.
Methods—Pathologic reports of all patients who had undergone upper endoscopy with biopsy 
between January 1, 2000 and June 20, 2013 were reviewed. Eosinophilic gastroenteritis was 
diagnosed if there were ≥20 eosinophils/hpf on either gastric of duodenal biopsy, symptoms 
attributable to the gastrointestinal tract, and no known secondary cause of eosinophilia. 
Descriptive statistics characterized patients diagnosed with eosinophilic gastroenteritis and 
bivariate analysis compared adults and children.
Results—There were 44 patients diagnosed with eosinophilic gastrointestinal disease. The most 
common symptoms were vomiting (71%) and abdominal pain (62%). Of the eosinophilic 
gastroenteritis cases, 12 (30%) had esophageal involvement, and 11 (28%) had colonic 
involvement. For treatment, 36 (80%) received corticosteroids. Overall, 27 (60%) had symptom 
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resolution and 23 (51%) had endoscopic resolution. Cases underwent a mean of five endoscopic 
procedures per year.
Conclusion—Eosinophilic gastroenteritis presents with non-specific gastrointestinal symptoms 
and in almost one-third of cases has concomitant esophageal or colonic involvement. It remains 
difficult to treat, with high rates of endoscopic utilization.
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1. Introduction
Eosinophilic gastroenteritis (EoG) is a rare condition first described in 1937 [1]. It belongs 
to the family of eosinophilic gastrointestinal disorders (EGID) where eosinophilic 
inflammation occurs in the GI tract in the absence of secondary causes. Proposed secondary 
causes include adrenal insufficiency, medication hypersensitivity reactions, collagen 
vascular disease, malignancy, hypereosinophilic syndrome, or parasitic infection [2,3].
Though the aetiology and pathogenesis of the disease have yet to be fully elucidated, the 
condition is thought to be a polygenic allergic disorder on the spectrum between IgE 
mediated and delayed Th2 responses, but not fitting completely into either category [2,4]. 
Case reports suggest that EoG has no singular ethnic or age predilection. It may be more 
prevalent from the 3rd to 5th decades of life [5,6]. The disease has been associated with 
atopic conditions including food allergy, asthma, and atopic dermatitis [7]. As described by 
Klein and Talley, there can be eosinophilic infiltration throughout the different layers of the 
GI tract (mucosal, muscle layer, subserosal) [8,9]. This and the location of the eosinophilia 
in the GI tract impact the clinical presentation, and help to explain the diverse symptoms and 
signs that may be attributable to the condition. Endoscopic or full-thickness surgical biopsy 
demonstrating eosinophilic infiltration of the GI tract is necessary to make the diagnosis of 
EoG [10–12].
Because the current literature is limited to small case series and single case reports, there are 
limited epidemiologic, clinical, and histopathologic data describing the disease. This makes 
diagnosis and treatment challenging, as there are no consensus statements to guide the 
evidence-based management of this condition. The aim of this study was to characterize the 
clinical, endoscopic, and histopathologic features of a cohort of patients with EoG, and to 
summarize treatment outcomes and resource utilization.
2. Materials and methods
We conducted a retrospective cohort study at the University of North Carolina at Chapel 
Hill. Pathology reports of all patients who had undergone upper endoscopy with biopsy 
between January 1, 2000 and June 20, 2013 were obtained to identify patients with EoG. 
These reports were reviewed if the term “eosinophil” was mentioned anywhere in the report. 
Cases of EoG were defined by ≥20 eosinophils/hpf (hpf = 0.24 mm2) on either gastric or 
duodenal biopsy, symptoms attributable to the GI tract (i.e. abdominal pain, nausea, 
vomiting, weight loss, feeding intolerance, etc.), and no known secondary cause of 
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eosinophilia. While there are no diagnostic guidelines published for EoG, this definition is 
consistent with what has been used in prior reports [9,13,14]. Colonoscopy reports from the 
same day as the index endoscopy were obtained to identify patients who also had colonic 
involvement.
Once cases were identified, additional data were extracted from the electronic medical 
record. These included patient demographics, symptoms, co-morbidities, habits (tobacco and 
alcohol abuse), medications, endoscopic findings, age specific BMI, and treatments. 
Symptoms were from patient or caregiver self-report. Comorbid conditions or disease 
complications required a diagnosis by a provider. Protein-losing enteropathy was defined by 
an albumin level less then 2.6 without hepatic dysfunction or proteinuria; ascites required a 
radiographic diagnosis. For patients with follow-up data available in our system, we 
assessed treatment outcomes including symptomatic, endoscopic, and histologic response. 
Interval changes in patient symptoms were also from self-report. All follow-up evaluations 
were done at the discretion of the physician to detail treatment response or to clarify 
recurrent symptoms. Endoscopic and histopathologic findings after treatment were 
compared with pre-treatment findings, but endoscopic response was only assessed for those 
patients with abnormal endoscopic findings at baseline. The total number of endoscopic 
procedures performed on patients during the follow-up period was also recorded.
For analysis, patients were characterized with descriptive statistics. Bivariate analysis was 
performed to compare adults (≥18 years) and children using t-tests for means and chi-square 
for proportions. We also calculated the mean number of endoscopic procedures performed 
per patient during the follow-up time frame. This study was approved by the UNC 
Institutional Review Board.
3. Results
There were 44 patients diagnosed with EGID over the study time frame. Four of these 
patients were diagnosed with isolated eosinophilic colitis (EoC) without involvement of the 
stomach or bowel. The mean age was 16 years (range 0.4–83), 58% were male, and 58% 
were white. The most common presenting symptoms were vomiting (71%) and abdominal 
pain (62%) (Table 1). While the mean BMI at diagnosis was normal (20 ± 7), the median 
BMI was in the underweight category (17, IQR: 16–23). Food allergies were noted in 42%, 
64% had a family history of atopic disease, and both the serum total IgE levels and 
peripheral eosinophil counts were elevated (Table 2).
Eosinophilic infiltration of the gastrointestinal tract varied for this population. Of the EoG 
cases, 12 (30%) had both gastric and duodenal involvement, 18 (45%) had gastric 
involvement only, and 10 had duodenal involvement only. In addition, we found that 12 
(30%) had esophageal involvement (eosinophilic esophagitis [EoE]) and 11 (28%) had 
colonic involvement (EoC). The average of the peak eosinophil counts were 61, 55, 56, and 
84 for the stomach, duodenum, oesophagus, and colon respectively (Table 2).
Endoscopic exams were normal in 21 (47%) of patients. Esophageal white plaques and 
esophagitis were found in 4 (9%) of those studied and these patients all had eosinophilic 
infiltration of the oesophagus. The most common gastric and duodenal finding was mucosal 
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erythema. For diagnosis and treatment monitoring, EGID cases underwent a mean of 5 ± 4 
endoscopic procedures per year (Table 3).
For treatment, 36 (80%) received corticosteroids, 21 (47%) had dietary restriction, and 34 
(76%) required >1 treatment modality. Budesonide, either in viscous slurry or enteral release 
formulations, was prescribed for 30 patients with doses ranging from 0.25 mg twice daily to 
9 mg once a day. Prednisone was prescribed for 10 patients with doses ranging from 5 to 40 
mg daily. Fluticasone was also prescribed for 3 patients at either 110 mcg or 220 mcg daily. 
Twenty-one patients were treated with dietary elimination; 13 were placed on an elemental 
formula; 7 received an elimination diet targeted after allergy testing; 1 patient’s dietary 
modification was not specified. Detailed clinical, endoscopic, histologic, and treatment 
information for each patient is presented in Supplementary Table S1.
To assess treatment outcomes, patients had a mean follow-up of 26.2 months, which 
encompassed an average of 6.6 Gastroenterology clinic encounters over the study period. In 
addition, patients underwent an average of 5 endoscopies per year (Fig. 1). In regards to 
treatment response, 27 (60%) had symptom resolution and 23 (51%) had endoscopic 
resolution on repeat endoscopic evaluation. When repeat biopsies were obtained, 20/29 
(69%) had histologic resolution with treatment. Ongoing eosinophilic inflammation with 
≥20 eos/hpf was found in 5/29 (17%) patients and non-specific changes were reported in 
4/29 patients (14%) patients. The degree of continued eosinophilic infiltration demonstrated 
a wide range from 68 to 500 eos/hpf. Of patients with histologic resolution, 63% had 
symptomatic resolution and 95% had endoscopic resolution; 27% had resolution in all three 
areas.
Higher response rates were noted for oral steroids than for diet modification, leukotriene 
antagonists, H2 blockers, or mast-cell inhibitors. Twenty-two of the 36 patients receiving 
corticosteroids reported symptom resolution. Twelve of the 21 patients who received dietary 
modification noted symptom resolution. However, 15 of these 21 patients also received 
corticosteroids during their treatment course (Table 4).
When adult and children with EoG were compared, the two groups had similar laboratory 
findings, endoscopic findings, treatment modalities, and symptom resolution per treatment 
responses. Demographic data suggested that the prevalence of EGID is greater in male 
children and female adults (Table 5). When those with symptomatic resolution (n = 15; 
44%) were compared to non-symptom responders, no statistically significant differences in 
clinical or endoscopic features were found (Supplementary Table S2).
4. Discussion
EoG is a rare condition, and the epidemiology, clinical presentation, treatments, and 
outcomes have not been extensively described. The goal of this study was to present a large 
cohort of well characterized patients with EoG. There were several key findings. First, 
symptoms of EoG were non-specific. Second, there was frequent GI tract eosinophilia in 
other locations such as the oesophagus and colon, even though the majority of patients had a 
normal appearing mucosa. Because of this, it is important to have a high degree of suspicion 
of an EGID; if biopsies are not obtained from multiple areas of the GI tract, an accurate 
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diagnosis cannot be made. Finally, EoG was difficult to treat, with just over half having a 
treatment response, and many patients required multiple endoscopies.
These findings extend what has previously been reported in the literature [8,9,14,15]. In 
seminal papers by Klein et al. and Talley et al. [8,9] non-specific symptoms such as nausea 
and abdominal pain were cardinal features, and a system classifying disease involvement of 
the bowel wall (mucosal, muscular, or subserosal) was described. Chang et al. extended the 
data published by Talley et al. in 2010 [9,14]. They described 59 adult patients with 
eosinophilic gastroenteritis reporting abdominal pain, nausea, and vomiting predominantly 
of the mucosal variant. A recently published series of 28 children with EoG also found that 
abdominal pain and vomiting were common, as were atopic diseases including asthma and 
food allergies [15].
Eosinophilic involvement of the gastrointestinal tract occurred in multiple locations in our 
population. Eosinophils were equally likely to be found in the stomach, duodenum, or both. 
In addition, one-third of patients had concurrent involvement of the oesophagus or colon. 
Laboratory data had relatively little utility in characterizing our patient population. Though 
markers associated with non-specific inflammation and allergy were consistently elevated, 
there was a high degree of variability in these values. Analysis of endoscopic features 
suggested that approximately one-half of patients have normal findings. The abnormal 
findings were also variable with no consistent feature noted.
Because we included patients of all ages in this study, we were able to compare the disease 
presentation in children to that in adults. Surprisingly, we found few differences in the two 
populations. Our data suggests that EGID may be more prevalent in male children and 
female adults. This is quite different than what has been reported for EoE, the best studied 
EGID [16–18].
Our data also show that treatment of EoG is difficult. Despite using a number of modalities, 
only one-half of our patients had symptomatic resolution over the study period, including 
those treated with corticosteroids. This is in contrast to other studies where steroid response 
rates ranged from 80% to 100% [6,14,15,19]. The lack of universal response to 
corticosteroids in our cohort of EoG patients may bring into question the true utility of this 
medication, especially in light of potential adverse effects, or may suggest non-allergic or 
non-immune mediated pathogenic mechanisms in some patients. We also did not observe 
the high rates of response to dietary elimination therapy that has also been recently reported 
[15]. In the context of this relatively unsuccessful treatment, management of EoG is also 
extremely resource intensive. Our patients required multiple endoscopies per year for 
diagnosis and monitoring of the disease. This emphasizes that in addition to more effective 
treatment, less invasive options for monitoring are needed.
The natural history and clinical course of EGID have yet to be fully characterized. A French 
study described the course of 43 adult patients with EGID over a mean follow-up period of 
13 years [20]. Three distinct patterns were observed: a single disease flare that lasted less 
than three months; a relapsing and remitting course; and a progressive disease course. It is 
difficult to infer natural history data from our study cohort as patients were treated rather 
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than observed. However, only one third remained in long-term remission, so many of our 
patients had a persistent or progressive disease course.
There are some limitations to this study. First, it has a retrospective design, which 
potentially introduces recall bias and limits the data that are available. For example, we do 
not have uniform data on depth of involvement (mucosal, muscular, or serosal) as full 
thickness biopsies are not part of routine practice and cross-sectional imaging is not 
performed in all subjects. In addition, symptom outcomes were subjective and must be 
interpreted with caution. However, we were able to use documented endoscopy and 
histologic findings to provide more objective outcome measures. Second, the study was 
from a single centre, so results may not be generalizable. However, we performed a 
comprehensive case-finding strategy that captured every case seen at our institution that had 
endoscopy and biopsy with active disease. We also cannot estimate the true prevalence of 
EoG based on this single centre study, but accounting for the total number of endoscopies 
performed over the study period (>144,000), we can calculate that EoG is seen in 
approximately 30/100,000 procedures. This is similar to a published prevalence estimate of 
28/100,000 [21]. While this is one of the largest series yet reported, the numbers are still 
relatively small so the study may be underpowered to detect differences between subgroups. 
Nevertheless, because of the cohort study design, we are able to provide important 
information about treatments, patient response, and resource utilization.
In conclusion, EoG presents with non-specific GI symptoms, and in almost one-third of 
cases involvement of the GI with eosinophils includes either the oesophagus or colon. 
Therefore, a high level of clinical suspicion with biopsies from all levels of the GI tract is 
required to make an accurate diagnosis. Once the diagnosis is made, EoG remains difficult 
to treat, with only just over half of patients in our cohort responding to treatment. Finally, 
management of EoG is resource intensive, with high rates of endoscopic utilization 
presenting a financial burden for many patients with EoG and their families.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Trends over time in endoscopic utilization in patients with eosinophilic gastrointestinal 
diseases. EGD, esophagogastroduodenoscopy.
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Table 1
Characteristics of subjects with eosinophilic gastrointestinal disorders.
Number of patients studied 44
Age at diagnosis, Mean ± SD; range 16.0 ± 19.1; 0.42–82.8
Length of sx before biopsy, Mean ± SD; range 4.9 ± 9.4; 0.08–55.7
Adult, ≥18; N (%) 11 (24)
Male, N (%) 26 (58)
Race, N (%)
 White 31 (58)
 Black 7 (16)
 Asian 0 (0)
 Hispanic 2 (4)
 Unknown 5 (11)
Symptoms, N (%)
 Dysphagia 12 (27)
 Heartburn 8 (18)
 Abdominal pain 28 (62)
 Nausea 17 (38)
 Vomiting 32 (71)
 Chest pain 3 (7)
 Bloating 8 (18)
 Diarrhoea 14 (31)
 Constipation 15 (33)
Comorbid conditions, N (%)
 Food allergy 19 (42)
 Asthma 12 (27)
 Allergic rhinitis 17 (38)
 Drug allergy 14 (31)
 Eczema 1 (16)
Complications, N (%)
 Family history of atopic disease 29 (64)
 Anaemia at diagnosis 4 (9)
 Failure to thrive 14 (31)
 Ascites 1 (2)
 Small bowel obstruction 1 (2)
 Food impaction 5 (11)
 Weight loss >4 pounds 12 (27)
 Protein losing enteropathy 3 (7)
 Steatorrhea 1 (2)
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Table 2
Laboratory and histologic findings of eosinophilic gastrointestinal disorder patients.
Lab results Mean ± SD Median IQR
Serum IgE level 418 ± 722 188 24–467
Absolute eosinophil count 1.53 ± 2.64 0.55 0.2–1.8
ESR 9.9 ± 11.3
CRP 2.9 ± 4.0 0.5 15.6–23.1
BMI 20.1 ± 6.9 16.7 15.6–23.1
Cases of EGID N = 44
EoG predominant, N (%) 40 (91)
 Gastric & Duodenal eosinophilia 12 (30)
 Gastric eosinophilia 18 (45)
 Duodenal eosinophilia 10 (25)
 EoE also present 12 (30)
 EoC also present 11 (28)
EoC predominant, N (%) 4 (9)
Eosinophil count (#/HPF) Mean ± SD Median IQR
Gastric 61 ± 70 37 25–60
Duodenal 55 ± 23 50 40–75
Esophageal 56 ± 62 42 9–100
Colonic eosinophil count 84 ± 73 68 50–80
EoG, eosinophilic gastroenteritis; EoE, eosinophilic esophagitis; EoC, eosinophilic colitis.
Serum IgE level (IU/L); Absolute eosinophil count (n * 109/l); ESR (mm/h); CRP (mg/dl); BMI (kg/m2).
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Table 3
Endoscopic data of subjects with eosinophilic gastrointestinal disorders.
Mean ± SD Range
Endoscopies performed 4 ± 5 1–23
Colonoscopies performed 0.8 ± 0.9 0–3
Average endoscopies and colonoscopies per year 5.4 ± 4.4 0.68–20







White plaques/exudates 4 (9)
Decreased vascularity 3 (7)
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Table 4
Therapeutic data of subjects with eosinophilic gastrointestinal disorders.
Pharmacologic therapy, N (%)
 Diet modification 21 (47)
 Mast cell inhibitor 2 (4)
 H-2 antagonist 18 (40)
 Leukotriene receptor antagonist 6 (13)
 Greater than 1 therapy 34 (76)
 Oral corticosteroids 36 (80)
  Systemic steroids 9 (25)
  Topical steroids 27 (75)
Repeat endoscopy performed 29 (66)
Response rate, N (%)
 Endoscopic resolution 23 (51)
 Symptom resolution 27 (61)
 Histologic resolution 20 (69)
Repeat endoscopy – esophagogastroduodenoscopy or colonoscopy.
Symptom resolution – 22/36 patients on steroids, 12/21 patients placed on dietary modification, 15/21 patients received both steroids and dietary 
modification.
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